{rfName}
Ma

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Nadal EAuthorRuffinelli JAuthorPardo JcAuthorPorta RAuthor

Share

August 2, 2020
Publications
>
Article
No

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

Publicated to:Lung Cancer. 147 83-90 - 2020-09-01 147(), DOI: 10.1016/j.lungcan.2020.06.034

Authors: Remon, J; Nadal, E; Dómine, M; Ruffinelli, J; García, Y; Pardo, JC; López, R; Cilleruelo, A; García-Campelo, R; Martín, P; Juan, O; González-Larriba, JL; Provencio, M; Olmedo, E; Ponce, S; Cumplido, D; Barenys, C; Majem, M; Massutti, B; Rodriguez-Abreu, D; Porta, R; Sala, MA; Martinez-Kareaga, M; Lianes, P; Reguart, N

Affiliations

Complejo Hospitalario Universitario Insular Materno-Infantil - Author
Hosp 12 Octubre, Med Oncol Dept, Madrid, Spain - Author
Hosp Badalona Germans Trias & Pujol, ICO Bellvitge, Inst Catala Oncol, Thorac Surg Dept, Barcelona, Spain - Author
Hosp Basurto, Med Oncol Dept, Vizcaya, Spain - Author
Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain - Author
Hosp Clin San Carlos, Med Oncol Dept, Madrid, Spain - Author
Hosp Clin Univ Valencia, Med Oncol Dept, Valencia, Spain - Author
Hosp Clin Univ Valladolid, Med Oncol Dept, Valladolid, Spain - Author
Hosp Clin Univ Valladolid, Thorac Surg Dept, Valladolid, Spain - Author
Hosp Josep Trueta, Inst Catala Oncol, Med Oncol Dept, ICO Girona, Girona, Spain - Author
Hosp Mataro, Med Oncol Dept, Barcelona, Spain - Author
Hosp Materno Infantil Teresa Herrera, Med Oncol Dept, La Coruna, Spain - Author
Hosp Ramon & Cajal, Med Oncol Dept, Madrid, Spain - Author
Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain - Author
Hosp Torrevieja, Med Oncol Dept, Alicante, Spain - Author
Hosp Univ & Politecn La Fe, Med Oncol Dept, Valencia, Spain - Author
Hosp Univ Alicante, Med Oncol Dept, Alicante, Spain - Author
Hosp Univ Araba Sede Txagorritxu, Med Oncol Dept, Vizcaya, Spain - Author
Hosp Univ Fdn Jimenez Diaz, Med Oncol Dept, Madrid, Spain - Author
Hosp Univ Insular Gran Canaria, Med Oncol Dept, Las Palmas Gran Canaria, Spain - Author
Hosp Univ Puerta Hierro, Med Oncol Dept, Madrid, Spain - Author
Hospital Clinic Barcelona - Author
Hospital Clinico San Carlos de Madrid - Author
Hospital Clínico Universitario de Valencia - Author
Hospital Clínico Universitario de Valladolid - Author
Hospital de la Santa Creu i Sant Pau - Author
Hospital de Mataró - Author
Hospital de Torrevieja - Author
Hospital General Universitario de Alicante - Author
Hospital Materno Infantil Teresa Herrera - Author
Hospital Ramón y Cajal - Author
Hospital Universitari de Bellvitge - Author
Hospital Universitari de Girona Dr. Josep Trueta - Author
Hospital Universitari Germans Trias i Pujol - Author
Hospital Universitari I Politècnic la Fe - Author
Hospital Universitario 12 de octubre - Author
Hospital Universitario de Araba (Sede Txagorritxu) - Author
Hospital Universitario Fundacion Jimenez Diaz - Author
Hospital Universitario Puerta de Hierro - Author
Inst Catala Oncol, ICO Bellvitge, Med Oncol Dept, Barcelona, Spain - Author
Inst Catala Oncol, Med Oncol Dept, Appl Res Grp Oncol B ARGO, Badalona, Spain - Author
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain - Author
Institut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS - Author
Institute Catala Oncologia - Author
Osakidetza, Basurto University Hospital - Author
Univ Autonoma Barcelona, Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT, Med Oncol Dept, Barcelona, Spain - Author
See more

Abstract

Keywords

chemotherapyepidemiologymalignant pleural mesotheliomaoutcomesradiotherapysurgeryAdultAgeAgedAntineoplastic metal complexArticleAsbestosCancer chemotherapyCancer combination chemotherapyCancer diagnosisCancer palliative therapyCancer radiotherapyCancer surgeryCancer survivalCancer therapyChemotherapyCisplatinClinical featureCohort analysisEpidemiologyEuropeExposureFemaleHistologyHumanMaintenance chemotherapyMajor clinical studyMaleMalignant pleural mesotheliomaMedian survival timeMultimodality cancer therapyOutcome assessmentOutcomesOverall survivalPemetrexedPhase-iiiPleura mesotheliomaPrimary health carePriority journalRadiotherapyRetrospective studySpainSurgerySurvivalTreatment outcomeTreatment responseTumor volume

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Lung Cancer due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2020, it was in position 13/64, thus managing to position itself as a Q1 (Primer Cuartil), in the category Respiratory System.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 3.96, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-16, the following number of citations:

  • WoS: 12
  • Scopus: 13
  • Europe PMC: 6

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 22.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 30 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 21.7.
  • The number of mentions on the social network X (formerly Twitter): 33 (Altmetric).